|
|
Article: Wyeth licenses VSV patents to GTx.
- Article from:
- Pharma Marketletter
- Article date:
- February 3, 2003
CopyrightCOPYRIGHT 2003 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
US firm GTx, which focuses on men's health, has entered into a cross-license and commercial option agreement with drug major Wyeth for vesicular stomatitis virus technologies.
Wyeth has exclusively sub-licensed to GTx patents covering VSV as cytolytic agents for use with the latter's proprietary VSV-based ...
Related newspaper, magazine, and journal articles:
|
|
Article: GTx Announces Webcast of Corporate Presentation at the ...
Business Wire;
August 30, 2007 ;
700+ words
...MEMPHIS, Tenn. -- GTx, Inc. (Nasdaq: GTXI) announced today ... Millennium Broadway Hotel in New York City. The GTx presentation will begin at 11 a.m. Eastern ... presentation will be accessible from the GTx website at www.gtxinc.com. An archived ...
|
|